about us

 

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaboration with partners, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.

 

Pulmatrix Profile – Health and Science Report

 

Pulmatrix’s iSPERSE™: An Engineered Solution to Effectively Treat Respiratory Diseases

 

 

Recent News
AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF
Aug 3, 2018

Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/1b clinical trial of Pulmazole. The data supports...

Jul 23, 2018

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the...

Jul 17, 2018

Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM...

Events
Monday, January 11, 2016
5:30pm - 6:00pm EST
Wednesday, March 9, 2016
11:20am - 11:50am EST

print email
 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design